Successful electroconvulsive therapy for depression in a man with cerebral amyloid angiopathy

Geert Schurgers,1 Baer M G Arts,1,2 Alida A Postma,2,3 Anna de Kort4,5

SUMMARY
Cerebral amyloid angiopathy (CAA) is a condition characterised by accumulation of amyloid beta protein (Aβ) in the wall of cerebral blood vessels which increases the risk of intracranial haemorrhage and contributes to cognitive impairment. We describe the case of a man around the age of 70 with ‘probable’ CAA according to the modified Boston criteria and severe depression whose depression was treated successfully with electroconvulsive therapy (ECT). To the best of our knowledge, there are no earlier published reports of ECT in a patient with CAA. We briefly discuss possible safety measures for these patients, the impact of ECT on cognition in CAA and a possible influence of ECT on Aβ clearance.

BACKGROUND
Cerebral amyloid angiopathy (CAA) is characterised by accumulation of amyloid beta protein (Aβ) in the wall of cerebral blood vessels, mainly cortical and leptomeningeal arterioles.1 It increases the risk of spontaneous intracranial haemorrhage and contributes to cognitive impairment.2 3 Possible psychiatric manifestations include personality changes, behavioural disturbances and/or depression.4 Diagnosis depends on the modified Boston criteria using pathologic, radiographic and/or clinical information.5 CAA is common: clinicopathological studies show a prevalence of 55%–59% in the demented and 28.6%–39% in the non-demented elderly population.6

Here, we describe the case of an elderly man with a history of intracranial haemorrhage with underlying ‘probable’ CAA according to the modified Boston criteria who underwent a successful course of electroconvulsive therapy (ECT). To the best of our knowledge, there are no earlier published reports of ECT in a patient with CAA. ECT is one of the most effective procedures for the treatment of depression with no absolute contraindications.7 Extra caution seems warranted in patients with a history of intracranial haemorrhage since ECT causes transient haemodynamic changes such as increased heart rate and blood pressure.8 However, successful ECT has been reported in a patient with recent subarachnoid haemorrhage9 or in the presence of subdural haemorrhage.10

This case is an example of a fundamental part of modern ECT practice: weighing potential benefits against risks and side-effects. After presenting the case, we discuss possible safety measures for patients with CAA, the impact of ECT on cognition in CAA and a possible influence of ECT on Aβ clearance.

CASE PRESENTATION
Our patient was a man around the age of 70 who was hospitalised due to spontaneous cerebral haemorrhage 12 months before admission to our psychiatric ward. MRI of the brain at the time of the cerebral haemorrhage revealed subarachnoid haemorrhage in the right central and precentral sulcus and a small focus of intraparenchymal bleeding in the left parietal lobe. The MRI scan also showed multiple microbleeds and superficial siderosis, both compatible with ‘probable’ CAA.5 Clinical signs of the stroke were minor disturbances of fine motor skills of the left hand but the patient recovered fully within weeks.

In the following months, the patient developed pain and loss of strength in his left leg. After extensive investigation, these problems were deemed functional. Six weeks prior to his hospitalisation at our ward, the patient’s physiotherapist told him no further improvement regarding his leg was to be expected. Since then the patient started to develop depressive symptoms for the first time in his life such as low mood, loss of interest in his surroundings, disrupted sleep, excessive worries and restlessness. Delusional thoughts (such as the false idea that he was going to lose his house) and catatonic signs (such as mutism, staring and perseveration) appeared in the following weeks. Ultimately, the patient was hospitalised at the psychiatric ward of our general university hospital after a primary care physician referred him to the emergency department.

Psychotic depression with catatonia was the preliminary diagnosis. Together with the aforementioned symptoms, the patient showed remarkable cognitive dysfunction such as disorientation, impaired memory and apraxia. The patient’s wife stated that her husband showed no signs of cognitive dysfunction up until the moment he started developing depressive symptoms.

INVESTIGATIONS
Routine blood testing and urinalysis showed no abnormalities. On admission to the psychiatric ward, brain MRI was repeated which showed similar results compared with the MRI scan 12 months earlier with no new cerebrovascular lesions (see figure 1). Cerebrospinal fluid (CSF) analysis revealed decreased levels of Aβ40 and Aβ42 (2632 (ref. >3200) and 385 (ref. >500) ng/L, respectively) with normal tau and phospho-tau levels (340 (ref. <350) and 48 (ref. <85) ng/L, respectively). The CSF sample showed no signs of inflammation of the central nervous system such as elevated leucocyte count or protein levels. When assessing
the patient’s cognitive functions, he attained a score of 25/30 on the Mini Mental State Examination (MMSE). More extensive neuropsychological examination objectified deficits in mental processing speed, attention, executive functions, memory and visuoconstruction (see Table 1).

DIFFERENTIAL DIAGNOSIS
Systemic causes of mood dysregulation such as anaemia and hypothyroidism were ruled out through blood testing. The (sub) acute time course of the cognitive deterioration and normal tau levels in the CSF made an advanced neurodegenerative condition such as Alzheimer’s disease (AD) unlikely. Although AD and CAA are overlapping conditions, the fact that not only Aβ1-40 but also Aβ1-42 levels in the CSF were decreased pointed to CAA rather than AD. Delirium was considered unlikely since apart from disorientation typical symptoms of delirium such as altered or fluctuating consciousness were absent. Also, typical causes of delirium such as infection or electrolyte disturbances were ruled out. Brain MRI excluded an acute cerebrovascular cause of the rapid cognitive decline. Psychotic depression was thus considered the main diagnosis and the patient was treated accordingly.

TREATMENT
Prior to hospitalisation, our patient was treated with sertraline up to 100 mg daily on an outpatient basis for several weeks with no success. Once he was hospitalised, lorazepam (1 mg three times a day) was initiated which led to the disappearance of the catatonic symptoms. Nortriptyline was started (50 mg once daily resulting in a therapeutic blood level of 1.34 μg/L) together with haloperidol (0.5 mg once daily) to treat the depressive symptoms and nihilistic delusions.

Despite psychopharmacological treatment for several weeks, the patient’s condition worsened. Eventually, a course of ECT was initiated. Evidence-based guidelines or case reports of ECT in patients with CAA were lacking. A neurologist specialised in neurovascular disease advised to avoid severe elevations in blood pressure during the procedure. To achieve this, the beta blocker esmolol (50 mg before the seizure, 50 mg once again after the seizure if needed) and the opioid agonist alfentanil (0.25–0.5 mg before the seizure) were administered intravenously to this 89 kg weighing man together with the usual anaesthetic (etomidate 20 mg) and muscle relaxant (succinylcholine 100 mg). Using this medication combination, the ictal and postictal systolic blood pressure did not exceed 160 mm Hg and the diastolic blood pressure stayed well below 100 mm Hg; these values were comparable to blood pressure measurements on non-ECT days. The patient underwent bitemporal ECT treatments twice weekly for a total of six ECT sessions (seizure duration 35–67 s on electroencephalogram) with the use of a Thymatron System IV device (Somatics, LLC, Lake Bluff, Illinois, USA). The following device parameters were used: pulse width=0.5 ms, frequency=50–70 Hz, stimulus duration=6.8–7.8 s and total charge=352–555 mC.

OUTCOME AND FOLLOW-UP
The ECT course was successful. Already after the first treatment, a clear improvement was seen as psychomotor retardation decreased significantly and the patient appeared remarkably more communicative. By the fourth treatment, the patient reported a dramatic improvement in his mood. ECT was stopped after the sixth treatment because remission was achieved. The total score on the clinician-rated Inventory of Depressive Symptomatology decreased from 25 pre-ECT (indicating moderate depression, probably an underestimation due to difficulties performing a complete assessment of symptoms due to the severe mood and cognitive disturbance) to seven post-ECT (indicating remission of depressive symptomatology). The subscore for anxiety on the Hospital Anxiety and Depression Scale decreased from 13/21 to 1/21, for depression from 13/21 to 4/21.

To assess whether the ECT was inflicting additional cerebral lesions, brain MRI was repeated after the fourth ECT treatment. No changes in the extent of superficial hemosiderosis or white matter hyperintensities and the number of microbleeds were observed nor new lesions or oedema. We did not observe any complications during the ECT course although cognitive problems persisted. The MMSE scores dropped from 25/30 pre-ECT to 24/30 during the ECT course. Three weeks post-ECT, a neuropsychological re-evaluation took place. The patient’s MMSE score now was 29/30 and improvements in working speed, attention and executive functions were seen, most likely due to resolution of depressive symptomatology. In contrast, impairments in memory and visuoconstructual abilities persisted (see Table 1). The remaining cognitive impairment was attributed to the cognitive side-effects of ECT and pre-existing cerebrovascular damage. Cognition improved in the months after ECT and

Figure 1 MRI (A, B, C) and CT (D) images of the brain made prior to electroconvulsive therapy. White matter hyperintensities (straight white arrows) classified as Fazekas grade 2 are seen at T2-weighted (A) and fluid-attenuated inversion recovery images (B). Subarachnoid haemorrhage (black arrowheads) in the right parietal region is seen at susceptibility weighted imaging (SWI) (C) and CT (D) with superficial haemorrhage (black arrowheads) in the right parietal region is seen at SWI (C). Intraparenchymal haemorrhage (white arrowhead) in the left parietal gyrus is seen at SWI (C) and CT (D). Microbleeds (bended arrows) are seen at SWI (C).

2 Schurgers G, et al. BMJ Case Rep 2021;14:e238922. doi:10.1136/bcr-2020-238922

BMJ Case Rep. first published as 10.1136/bcr-2020-238922 on 5 February 2021. Downloaded from http://casereports.bmj.com/ on September 17, 2023 by guest. Protected by copyright.
remained stable thereafter, according to the patient’s wife. In the year after ECT, there were no signs of depression relapse.

DISCUSSION
To the best of our knowledge, this is the first case report of successful ECT in a patient with ‘probable’ CAA. Given the high prevalence of CAA in the elderly and the fact that ECT is a preferred treatment method in severe late-life depression,14 it is likely that many patients with unrecognised CAA are treated with ECT, without specific safety measures. Considering the low rates of serious ECT-related adverse events in large patient populations,15–17 one could argue that the risk of provoking intracerebral haemorrhage is probably low. However, Weisberg et al reported a case of intracerebral haemorrhage following ECT in which CAA was considered a possible underlying cause.18 It is unclear whether or not specific safety measures (such as neuroimaging prior to/during ECT or interventions to reduce periprocedural blood pressure) provide safety benefits in patients with probable CAA. Evidence-based guidelines on this matter are lacking. Esmolol seems to be a good candidate to reduce blood pressure and heart rate after electrical stimulation but shortening of the seizure duration could possibly impede ECT efficacy.19

Adjuvant remifentanil has proven to reduce systolic blood pressure and heart rate after electrical stimulation but shortening of the seizure duration could possibly impede ECT efficacy.19,20 It is unclear whether or not specific safety measures (such as neuroimaging prior to/during ECT or interventions to reduce periprocedural blood pressure) provide safety benefits in patients with probable CAA. Evidence-based guidelines on this matter are lacking. Esmolol seems to be a good candidate to reduce blood pressure and heart rate after electrical stimulation but shortening of the seizure duration could possibly impede ECT efficacy.19

Table 1 Overview of specific neuropsychological tests performed prior to ECT and 3 weeks after completion of the ECT course

| Name of test | Cognitive functions assessed | Performance pre-ECT | Performance post-ECT |
|--------------|------------------------------|---------------------|---------------------|
| CST          | • CST A: attention, processing speed | • CST A: extremely low (Z = −4.32) | • CST A: low average (Z = −0.94) |
|              | • CST B: attention, processing speed | • CST B: low average (Z = −1.45) | • CST B: superior (Z = 1.31) |
|              | • CST C: mental flexibility | • CST C: extremely low (Z = −3.32) | • CST C: extremely low (Z = −4.81) |
|              | • CST interference score: mental flexibility | • CST interference score: extremely low (Z = −2.81) | • CST interference score: extremely low (Z = −6.84) |
| SCWT         | • SCWT 1: attention, processing speed | • SCWT 1: extremely low (Z = −2.08) | • SCWT 1: average (Z = −0.05) |
|              | • SCWT 2: attention, processing speed | • SCWT 2: low average (Z = −1.30) | • SCWT 2: low average (Z = −1.09) |
|              | • SCWT 3: selective attention, ability to inhibit cognitive interference | • SCWT 3: average (Z = −0.51) | • SCWT 3: average (Z = −0.42) |
|              | • SCWT interference score: inhibition | • SCWT interference score: average (Z = 0.1) | • SCWT interference score: average (Z = −0.31) |
| LDST         | Processing speed, writing, reading | • Writing: extremely low (Z = −3.9) | • Writing: borderline/low (Z = −1.77) |
|              | • Reading: extremely low (Z = −2.56) | • Reading: low average (Z = −1.19) |
| BADS         | Executive functions | Total score 3 (impaired) | Total score 11 (borderline) |
| 15-Words Test | Memory: immediate recall, delayed recall, recognition | • Immediate: borderline (Z = −1.61) | • Immediate: extremely low (Z = −2.38) |
|              | • Delayed: extremely low (Z = −2.94) | • Delayed: extremely low (Z = −2.14) |
|              | • Recognition: borderline (Z = −1.61) | • Recognition: borderline (Z = −1.95) |
| VAT          | Memory: learning visual associations | Percentile 1 (extremely low) | Percentile 1 (extremely low) |
| Visuoconstruction tests (drawing of meander pattern, cubes, honeycomb, clock) | Visuoconstruction | Clock drawing ‘poor’, rest ‘wrong’ (rating: good—poor—wrong) | Cube drawing ‘poor’, rest ‘wrong’ (rating: good—poor—wrong) |
| BNT          | Naming | Score 13/15 (above cut-off, which is 12.5) | Score 14/15 (above cut-off, which is 12.5) |

Z-scores <2.00 indicate impairment.

BADS, Behavioural Assessment of the Dysexecutive Syndrome; BNT, Boston Naming Test; CST, concept shifting task; ECT, electroconvulsive therapy; LDST, Letter Digit Substitution Test; SCWT, Stroop Colour and Word Test; VAT, Visual Association Test.
with AD 20 months after unilateral ECT, possibly due to ECT-induced alterations in Aβ deposition.26 Altered Aβ deposition might be a consequence of glial cell activation by ECT.27 Clearly, further research in this area is needed before firm conclusions can be drawn. Unfortunately, we did not have the possibility to re-examine the CSF of our patient so we cannot make statements on the impact of ECT on Aβ in this specific case.

**Learning points**

► This is the first case report of electroconvulsive therapy (ECT) in a patient with depression and cerebral amyloid angiopathy (CAA), a common condition among elderly characterised by accumulation of amyloid beta protein (Aβ) in the wall of cerebral blood vessels leading to intracranial haemorrhage and cognitive impairment.

► Following a vascular neurologist’s advice, we used a beta blocker and opioid antagonist to limit blood pressure during ECT and reduce the risk of cerebral haemorrhage. We performed brain MRI after four ECT treatments to assess whether ECT was inflicting additional cerebral lesions, which was not the case. Evidence-based guidelines on such safety measures for patients with CAA are non-existent.

► Our case suggests ECT should be considered in elderly patients with severe mood disorders even in the presence of CAA.

► Preliminary evidence suggests that ECT stimulates Aβ elimination from the brain but further research is needed before firm conclusions can be drawn.

**Acknowledgements** Dr Marcel M. Verbeek and Professor Pascal Sienaert, renowned experts in the fields of CAA and ECT, respectively, provided additional advice and assisted in selecting an appropriate journal for publication of the manuscript. Dr Claire Wolfs assisted in interpreting and summarising the neuropsychological findings.

**Contributors** GS was directly involved in the treatment of the patient described in the article, took the initiative to write this case report and was the main author of the manuscript. BMGA was the supervising psychiatrist involved in the treatment of the patient and critically revised multiple versions of the manuscript. AAP critically revised multiple versions of the manuscript, especially the parts on neuropsychological aspects, and provided the images. AD critically revised multiple versions of the manuscript, especially the parts on clinical and pathophysiological aspects of cerebral amyloid angiopathy.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** AAP reports an institutional grant from Siemens Healthcare, which licenses/life-deadline under a non-commercial, non-transferable license to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iD**

Geert Schurgers http://orcid.org/0000-0003-4343-5242

**REFERENCES**

1. Attems J, Jellinger K, Thal DR, et al. Review: sporadic cerebral amyloid angiopathy. *Neuropathol Appl Neurobiol* 2011;37:75–93.

2. Charidimou A, Gang Q, Werring DJ. Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum. *J Neurol Neurosurg Psychiatry* 2012;83:124–37.

3. Banerjee G, Carare R, Cordonnier C, et al. The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice. *J Neurol Neurosurg Psychiatry* 2017;88:982–94.

4. Gahr M, Nowak DA, Connenmann BJ, et al. Cerebral amyloid angiopathy - A disease with implications for neurology and psychiatry. *Brain Res* 2013;1519:19–30.

5. Linn J, Jlapin A, Denaerep P, et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. *Neurology* 2010;74:1346–50.

6. Keage HAD, Carare RO, Friedland RP, et al. Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review. *BMC Neurol* 2009;9:3.

7. Sienaert P. What we have learned about electroconvulsive therapy and its relevance for the practising psychiatrist. *Can J Psychiatry* 2011;56:5–12.

8. Van Herck E, Sienaert P, Hagon A. Elektrokonvulsivtherapie bei Patienten mit intrazerebraler aneurysmatosa: gevalsbespreking en overzicht van de literatuur. *Tijdschr Psychiatr* 2009;51:43–51.

9. Dodd SR, Lotz M, Regenold WT, et al. Electroconvulsive therapy in a patient with a recent subarachnoid hemorrhage. *J Ect* 2018;34:e2–4.

10. Wijeratne C, Shome S. Electroconvulsive therapy and subdural hemorrhage. *J Ect* 1999;15:1–9.

11. Greenberg SM, Bacskai BJ, Hernandez-Guillaum M, et al. Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. *Nat Rev Neurol* 2020;16:20–42.

12. Ritchie C, Smalagic N, Noel-Storr AH, et al. CSF tau and the CSF tau/Aβ ratio for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). *Cochrane Database Syst Rev* 2017;3:CD010803.

13. Charidimou A, Friedrich JO, Greenberg SM, et al. Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: a meta-analysis. *Neurology* 2018;90:e754–62.

14. Geduldig ET, Kellner CH. Electroconvulsive therapy in the elderly: new findings in geriatric depression. *Curr Psychiatry Rep* 2016;18:40.

15. Blumberg DM, Seitz DP, Hermann N, et al. Low medical morbidity and mortality after acute courses of electroconvulsive therapy in a population-based sample. *Acta Psychiatr Scand* 2017;136:583–93.

16. Nuttall GA, Bowersox MR, Douglass SB, et al. Morbidity and mortality in the use of electroconvulsive therapy. *J Ect* 2004;20:237–41.

17. Watts BV, Groft A, Bagian JP, et al. An examination of mortality and other adverse events related to electroconvulsive therapy using a national adverse event report system. *J Ect* 2011;7:105–8.

18. Weisberg LA, Elliott D, Meille D. Intracerebral hemorrhage following electroconvulsive therapy. *Neurology* 1991;41:1849.

19. Boere E, Birkenhager TK, Groenland THN, et al. Beta-blocking agents during electroconvulsive therapy: a review. *Br J Anaesth* 2014;113:43–51.

20. Takekita Y, Suwa T, Sunada N, et al. Remifentanil in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials. *Eur Arch Psychiatry Clin Neurosci* 2016;266:703–17.

21. Ollibon J, Vansteelandt K, Verwijk E, et al. MMSE changes during and after ECT in late-life Depression: a prospective study. *Am J Geriatr Psychiatry* 2019;27:994–44.

22. Bourkaert F, Emsli L, Vansteelandt K, et al. Electroconvulsive therapy response in late-life depression unaffected by age-related brain changes. *J Affect Disord* 2019;251:114–20.

23. Zimmermann R, Schmitt H, Rotter A, et al. Transient increase of plasma concentrations of amyloid β peptides after electroconvulsive therapy. *Brain Stimul* 2012;5:25–9.

24. Kranaster L, Aksay SS, Bumb JM, et al. Electroconvulsive therapy selectively enhances amyloid β (1-42) in the cerebrospinal fluid of patients with major depression: a prospective pilot study. *Eur Neuropsychopharmacol* 2016;26:1877–84.

25. Andrade C, Bolwig TG, therapy E. Electroconvulsive therapy, hypertensive surge, blood-brain barrier breach, and amnesia: exploring the evidence for a connection. *J Ect* 2014;30:160–4.

26. Vandenbulcke M, Bourkaert F, De Winter F, et al. Asymmetrical amyloid deposition in the brain following unilateral electroconvulsive therapy. *Biol Psychiatry* 2017;81:11–13.

27. Jansson L, Wennström M, Johanson A, et al. Giall cell activation in response to electroconvulsive seizures. *Prog Neuropsychopharmacol Biol Psychiatry* 2009;33:1119–28.
